Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer

Journal of the National Cancer Institute

Volumn 105, Issue 10, 2013, Pages 711-718

  Hoffman, Richard M ^a,b   Koyama, Tatsuki ^j   Fan, Kang Hsien ^j   Albertsen, Peter C ^c   Barry, Michael J ^d   Goodman, Michael ^e   Hamilton, Ann S ^f   Potosky, Arnold L ^g   Stanford, Janet L ^h   Stroup, Antoinette M ⁱ   Penson, David F ^k,l  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j Center for Communication Science RTI International   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DEMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84878000536     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt059     Document Type: Article

References (33)

1. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004;5(3):166-172.
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18): 1708-1717.
3. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6): 435-448.
5. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;(10):CD001431.
6. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91(20):1719-1724.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
8. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Med Care. 2005;43(4):391-400.
9. Office of Health Statistics. Instruction Manual. Part 2c, ICD-9 ACME Decision Tables for Classifying Underlying Causes of Death. Hyattsville, MD: Department of Health and Human Services, Public Health Service; 1981.
10. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757-763.
11. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate. 1992;21(S4):129-138.
12. Gleason DF. Histologic grading of prostate cancer: a perspective. Human Pathol. 1992;23(3):273-279.
13. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994.
14. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004;91(7):1229-1235.
15. Greevy RA, Grijalva CG, Roumie CL. Reweighted Mahalanobis distance matching for cluster-randomized trials with missing data-Greevy-2012- Pharmacoepidemiology and Drug Safety-Wiley Online Library and Drug Safety. 2012.
16. Lu B, Greevy R, Xu X, Beck C. Optimal nonbipartite matching and its statistical applications. Am Stat. 2011;65(1):21-30.
17. Robins JM, Hernán MÁ, Brumback B. Marginal Structural Models and Causal Inference in Epidemiol.: Epidemiology. Epidemiology. 2000.
18. Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29(20):2137-2148.
19. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Meth. 2010;15(3):234-249.
20. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107-118.
21. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827.
22. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R. SEER Cancer Statistics Review 1975-2007. Bethesda, MD: National Cancer Institute, 2009.
23. Widmark A. Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer (T1b-T2, pN0, Grade 1-2, M0). American Society for Radiation Oncology (ASTRO). Miami Beach, FL.
24. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516-2527.
25. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92(3):488-498.
26. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-131.
27. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011.
28. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011;29(2): 228-234.
29. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43(4):316-381.
30. Wong Y-N, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006; 296(22):2683-2693.
31. Litwin MS, Miller DC. Treating older men with prostate cancer: survival (or selection) of the fittest? JAMA. 2006;296(22):2733-2734.
32. Litwin MS, Greenfield S, Elkin E P, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007;109(9): 1777-1783.
33. Daskivich TJ, Chamie K, Kwan L, et al. Improved prediction of long-term, other cause mortality in men with prostate cancer. J Urol. 2011;186(5): 1868-1873.